Marshall Wace’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $273K | Sell |
353
-478,198
| -100% | -$366M | ﹤0.01% | 2680 |
|
|
2025
Q4 | $369M | Buy |
478,551
+91,667
| +24% | +$62.3M | 0.34% | 40 |
|
|
2025
Q3 | $218M | Buy |
386,884
+146,975
| +61% | +$83.1M | 0.22% | 65 |
|
|
2025
Q2 | $126M | Buy |
239,909
+238,509
| +17,036% | +$133M | 0.14% | 128 |
|
|
2025
Q1 | $888K | Sell |
1,400
-126,000
| -99% | -$86.7M | ﹤0.01% | 1837 |
|
|
2024
Q4 | $90.8M | Sell |
127,400
-6,604
| -5% | -$5.54M | 0.11% | 169 |
|
|
2024
Q3 | $141M | Buy |
134,004
+75,131
| +128% | +$83.6M | 0.17% | 96 |
|
|
2024
Q2 | $61.9M | Sell |
58,873
-141,514
| -71% | -$137M | 0.08% | 228 |
|
|
2024
Q1 | $193M | Buy |
200,387
+105,861
| +112% | +$101M | 0.29% | 56 |
|
|
2023
Q4 | $83M | Sell |
94,526
-10,751
| -10% | -$8.85M | 0.14% | 143 |
|
|
2023
Q3 | $86.6M | Sell |
105,277
-38,231
| -27% | -$30M | 0.18% | 112 |
|
|
2023
Q2 | $103M | Buy |
143,508
+52,710
| +58% | +$40.6M | 0.2% | 102 |
|
|
2023
Q1 | $74.6M | Buy |
90,798
+81,098
| +836% | +$61.2M | 0.16% | 136 |
|
|
2022
Q4 | $7M | Buy |
9,700
+5,595
| +136% | +$4.13M | 0.02% | 1003 |
|
|
2022
Q3 | $2.83M | Sell |
4,105
-47,950
| -92% | -$30.2M | 0.01% | 1790 |
|
|
2022
Q2 | $30.8M | Buy |
52,055
+48,188
| +1,246% | +$31.3M | 0.06% | 321 |
|
|
2022
Q1 | $2.7M | Sell |
3,867
-125,161
| -97% | -$79.2M | 0.01% | 1859 |
|
|
2021
Q4 | $81.5M | Buy |
129,028
+25,056
| +24% | +$15.4M | 0.15% | 129 |
|
|
2021
Q3 | $62.9M | Buy |
103,972
+31,520
| +44% | +$19.6M | 0.26% | 61 |
|
|
2021
Q2 | $40.5M | Buy |
72,452
+54,384
| +301% | +$27.6M | 0.18% | 105 |
|
|
2021
Q1 | $8.55M | Buy |
18,068
+15,448
| +590% | +$7.52M | 0.04% | 541 |
|
|
2020
Q4 | $1.27M | Buy |
+2,620
| New | +$1.41M | 0.01% | 1123 |
|
|
2020
Q3 | – | Sell |
-13,270
| Closed | -$8.28M | – | 1869 |
|
|
2020
Q2 | $8.28M | Buy |
+13,270
| New | +$7.53M | 0.06% | 336 |
|
|
2020
Q1 | – | Sell |
-26,276
| Closed | -$9.87M | – | 1992 |
|
|
2019
Q4 | $9.87M | Buy |
26,276
+17,461
| +198% | +$5.87M | 0.07% | 322 |
|
|
2019
Q3 | $2.45M | Sell |
8,815
-112,360
| -93% | -$33.2M | 0.02% | 706 |
|
|
2019
Q2 | $37.9M | Buy |
+121,175
| New | +$40.3M | 0.31% | 58 |
|
|
2019
Q1 | – | Sell |
-1,303
| Closed | -$487K | – | 2007 |
|
|
2018
Q4 | $487K | Buy |
+1,303
| New | +$477K | 0.01% | 1101 |
|
|
2018
Q3 | – | Sell |
-8,703
| Closed | -$3M | – | 1260 |
|
|
2018
Q2 | $3M | Buy |
+8,703
| New | +$2.72M | 0.04% | 371 |
|
|
2017
Q1 | – | Sell |
-26,755
| Closed | -$9.82M | – | 665 |
|
|
2016
Q4 | $9.82M | Buy |
26,755
+17,116
| +178% | +$6.51M | 0.06% | 345 |
|
|
2016
Q3 | $3.88M | Sell |
9,639
-11,256
| -54% | -$4.52M | 0.03% | 462 |
|
|
2016
Q2 | $7.3M | Buy |
20,895
+7,675
| +58% | +$2.96M | 0.06% | 315 |
|
|
2016
Q1 | $4.76M | Buy |
13,220
+12,626
| +2,126% | +$5.2M | 0.05% | 357 |
|
|
2015
Q4 | $322K | Sell |
594
-14,528
| -96% | -$7.87M | ﹤0.01% | 868 |
|
|
2015
Q3 | $7.03M | Buy |
+15,122
| New | +$8.12M | 0.09% | 235 |
|
|
2015
Q2 | – | Sell |
-647
| Closed | -$292K | – | 1022 |
|
|
2015
Q1 | $292K | Buy |
+647
| New | +$274K | ﹤0.01% | 725 |
|
|
2014
Q4 | – | Sell |
-36,583
| Closed | -$13.2M | – | 934 |
|
|
2014
Q3 | $13.2M | Buy |
36,583
+21,746
| +147% | +$7.29M | 0.19% | 147 |
|
|
2014
Q2 | $4.19M | Buy |
+14,837
| New | +$4.4M | 0.06% | 289 |
|
Other funds holding REGN
VCM
N
Marshall Wace's REGN Position: Q1 2026 in Review
Marshall Wace reduced its Regeneron Pharmaceuticals (REGN) stake by 100% in Q1 2026, selling an estimated $366M and leaving 353 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2680.
Marshall Wace first reported a position in REGN in Q2 2014 and has held it in 37 quarters since. The position peaked at $369M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Marshall Wace held 353 shares of Regeneron Pharmaceuticals worth $273K as of Q1 2026.
- Marshall Wace sold 478,198 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $366M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2680 holding.
- Marshall Wace first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 37 quarters since.
- Marshall Wace's Regeneron Pharmaceuticals position peaked at $369M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.